The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C medrxivpreprint EmoryUniversity WUSTLmed COVID19 coronavirus covid vaccination vaccine inflammation disease
By Dr. Chinta SidharthanNov 23 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to the medRxiv* preprint server, a team of researchers evaluated the serological responses elicited by coronavirus disease 2019 vaccinations in children who developed multisystem inflammatory syndrome following a previous severe acute respiratory syndrome coronavirus 2 infection.
About the study In the present study, the researchers enrolled children hospitalized with MIS-C, those who had positive polymerase chain reaction tests for symptomatic COVID-19, and healthy children as controls. Blood samples were collected to isolate plasma and serum. Pseudotyped lentiviral particles carrying the wildtype or Omicron subvariant spike proteins were used for neutralizing antibody assays. Additionally, the researchers used transfected target cells that expressed either the wildtype or Omicron spike proteins to perform antibody-dependent cell-mediated cytotoxicity assays.
The cross-reactive IgG antibodies increased after vaccination and were maintained at high levels for three months after vaccination. The antibody titers increased significantly after each BNT162b2 vaccine dose. The ELISA results showed that the antibodies against the receptor binding domain also increased after vaccination in all five children hospitalized with MIS-C.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
The negative impact of COVID-19 on working memory revealed using a rapid online quizAlthough coronavirus disease 2019 (COVID-19) affects the respiratory system, it can also have neurological consequences leading to cognitive deficits such as memory problems. The aim of our study was to assess the impact of COVID-19 on working memory function. We developed and implemented an online anonymous survey with a working memory quiz incorporating aspects of gamification to engage participants. 5428 participants successfully completed the survey and memory quiz between 8th December 2020 and 5th July 2021 (68.6% non-COVID-19 and 31.4% COVID-19). Most participants (93.3%) completed the survey and memory quiz relatively rapidly (mean time of 8.84 minutes). Categorical regression was used to assess the contribution of COVID status, age, time post-COVID (number of months elapsed since having had COVID), symptoms, ongoing symptoms and gender, followed by non-parametric statistics. A principal component analysis explored the relationship between subjective ratings and objective memory scores. The objective memory scores were significantly correlated with participants’ own assessment of their cognitive function. The factors significantly affecting memory scores were COVID status, age, time post-COVID and ongoing symptoms. Our main finding was a significant reduction in memory scores in all COVID groups (self-reported, positive-tested and hospitalized) compared to the non-COVID group. Memory scores for all COVID groups combined were significantly reduced compared to the non-COVID group in every age category 25 years and over, but not for the youngest age category (18–24 years old). We found that memory scores gradually increased over a period of 17 months post-COVID-19. However, those with ongoing COVID-19 symptoms continued to show a reduction in memory scores. Our findings demonstrate that COVID-19 negatively impacts working memory function, but only in adults aged 25 years and over. Moreover, our results suggest that working memory deficits with COVID-19 can recov
Læs mere »
European stocks slip on China Covid fears\n\t\t\tExpert insights, analysis and smart data help you cut through the noise to spot trends,\n\t\t\trisks and opportunities.\n\t\t\n\t\tJoin over 300,000 Finance professionals who already subscribe to the FT.
Læs mere »
Vanessa Feltz reveals her daughter is desperately ill in hospitalShe said that the doctor had told her family that flu can be 'worse than Covid'.
Læs mere »
CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to get safe, effective, and affordable COVID-19 treatments quickly is to repurpose drugs that are already approved for other diseases. The process of developing an accurate and standardized drug repurposing dataset requires considerable resources and expertise due to numerous commercially available drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx.org platform. CoviRx is a user-friendly interface that allows analysis and filtering of large quantities of data, which is onerous to curate manually for COVID-19 drug repurposing. Through CoviRx, the curated data have been made open source to help combat the ongoing pandemic and encourage users to submit their findings on the drugs they have evaluated, in a uniform format that can be validated and checked for integrity by authenticated volunteers. This article discusses the various features of CoviRx, its design principles, and how its functionality is independent of the data it displays. Thus, in the future, this platform can be extended to include any other disease beyond COVID-19.
Læs mere »